Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.38 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.38 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.38 |
| ▸ | DHPS | P49366 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6834462 | 0.87 | MEN1 (0.42) | MEN1KMT2AL3MBTL1ALB | |
| SCHEMBL6834154 | 0.86 | KMT2A (0.49) | NPC1RAB9AMEN1KMT2AALB | |
| SCHEMBL6833137 | 0.85 | MAP3K5 (0.44) | KMT2AALBRXFP1NHERF1 | |
| SCHEMBL6834115 | 0.85 | ALB (0.47) | MEN1KMT2AALBRXFP1TSHR | |
| SCHEMBL6835708 | 0.85 | CCKAR (0.51) | NPC1RAB9ANHERF1 | |
| SCHEMBL6834385 | 0.84 | SERPINE1 (0.51) | NPC1RAB9AKMT2AALBRXFP1 | |
| SCHEMBL6830877 | 0.84 | AKR1C2 (0.48) | MEN1KMT2AALBRXFP1TSHR | |
| SCHEMBL6833897 | 0.83 | ALB (0.42) | KMT2AALBRXFP1HDAC3HDAC1 | |
| SCHEMBL6835688 | 0.83 | GFER (0.45) | NPC1ALBRXFP1NHERF1 | |
| SCHEMBL6830151 | 0.83 | ALB (0.42) | KMT2AALBRXFP1NHERF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | NPC1 3778/4885RAB9A 4337/4885MEN1 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.